New: NCI-funded clinical trial search
Mednet Logo

For patients with VEXAS syndrome and good response to azacitidine, what duration of therapy do you consider?

How do you decide to trial a patient off treatment? When do you consider spacing therapy and at what frequency?
1 Answer
Mednet MemberInvited Expert
Hematology · Dalhousie University, Canada
Answered on

The short answer: as long as azacitidine is controlling inflammation, reducing/eliminating steroid dependence, and/or improving cytopenias, keep using it. Don't stop (or if the patient is being bridged to alloSCT, continue until BMT).

The long answer:

VEXAS is an autoinflammatory disease wherein patients often need high-dose corticosteroids (e.g. prednisone > 20 mg/day) for control of symptoms; a subset has overt MDS. The goals of systemic therapy are:

  1. Control inflammation and the end organ damage associated with inflammation (lung, skin, GI manifestations) - monitor the CRP
  2. Reduce or eliminate the need for corticosteroids
  3. Bridge to transplant for those pts eligible for alloSCT (the only curative option) - this is a small subset as most patie...

Join for free or sign in to see the full answer